Cyclophosphamide diminishes inflammation and prolongs transgene expression following delivery of adenoviral vectors to mouse liver and lung

Human Gene Therapy

Volumn 7, Issue 13, 1996, Pages 1555-1566

  Jooss, Karin ^b   Yang, Yiping ^b   Wilson, James M ^a  

^a WISTAR INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; CYCLOPHOSPHAMIDE; CYTOKINE; IMMUNOSUPPRESSIVE AGENT; NEUTRALIZING ANTIBODY;

ADENOVIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; B LYMPHOCYTE; BLOOD CELL COUNT; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG EFFECT; GENE EXPRESSION; GENE TARGETING; GENE THERAPY; GENE TRANSFER; IMMUNE RESPONSE; INFLAMMATION; INTRAVENOUS DRUG ADMINISTRATION; LIVER CELL; LUNG ALVEOLUS CELL; MOUSE; NONHUMAN; RECOMBINANT GENE; T LYMPHOCYTE ACTIVATION; TRANSGENE;

EID: 0029743163     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.1996.7.13-1555     Document Type: Article

References (27)

1. BARR, D., TUBB, J., FERGUSON, D., SCARIA, A., LIEBER, A., WILSON, C., PERKINS, J., and KAY, M. (1995). Strain related variations in adenovirally mediated transgene expression from mouse hepatocytes in vivo: comparisons between immunocompetent and immunodeficient inbred strains. Gene Ther. 2, 151-155.
2. BERGE, R.J. (1994). Immunosuppressive drugs in clinical medicine. Netherlands J. Med. 45, 329-338.
3. CHANG, T.K.H., WEBER, G.F., CRESPI, C.L., and WAXMAN, D.J. (1993). Differential activation of cyclophosphamide and ifosphamide by cytochromes P450 2B and 3A in human liver microsomes. Cancer Res. 53, 5629-5637.
4. CHEN, L., and WAXMAN, D. (1995). Intratumoral activation and enhanced chemotherapeutic effect of oxazaphosphorines following cytochrome P-450 gene transfer: development of a combined chemotherapy/cancer gene therapy strategy. Cancer Res. 55, 581-589.
5. CLARKE, L., and WAXMAN, D.J. (1989). Oxidative metabolism of cyclophosphamide: identification of the hepatic monooxygenase catalysts of drug activation. Cancer Res. 49, 2344-2350.
6. CRYSTAL, R. (1995). Transfer of genes to humans: early lessons and obstacles to success. Science 270, 404-410.
7. DAI, Y., SCHWARZ, E., GU, D., ZHANG, W., SARVETNICK, N., and VERMA, I. (1995). Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: Tolerization of factor IX and vector antigens allows for long-term expression. Proc. Natl. Acad. Sci. USA 92, 1401-1405.
8. ENGELHARDT, J.F., YE, X., DORANZ, B., and WILSON, J.M. (1994). Ablation of E2a in recombinant adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver. Proc. Natl. Acad. Sci. USA 91, 6196-6200.
9. FANG, B., EISENSMITH, R., WANG, H., KAY, M., CROSS, R., LANDEN, C., GORDON, G., BELLINGER, D., READ, M., HU, P., BRINKHOUS, K., and WOO, S. (1995). Gene therapy for hemophilia B: Host immunosuppression prolongs the therapeutic effect of adenovirus-mediated factor IX expression. Hum. Gene Ther. 6, 1039-1044.
10. KAY, M., HOLTERMAN, A.-x., MEUSE, L., GOWN, A., OCHS, H., LINSLEY, P., and WILSON, C. (1995). Long-term hepatic adenovirus-mediated gene expression in mice following CTLA4-Ig administration. Nature Genet. 11, 191-197.
11. KOHN, D.B., WEINBERG, K.I., NOLTA, J.A., HEISS, L.N., LENARSKY, C., CROOKS, G.M., HANLEY, M.E., ANNETT, G., BROOKS, J.S., EL-KHOURELY, A., LAWRENCE, K., WELLS, S., MOEN, R.C., BASTIAN, J., WILLIAMS-HERMAN, D.E., ELDER, M., WARA, D., BOWEN, T., HERSHFIELD, M.S., MULLEN, C.A., BLAESE, R.M., and PARKMAN, R. (1995). Engraftment of gene-modified umbilical cord blood cells in neonates with adenosine deaminase deficiency. Nature Med. 1, 1017-1023.
12. LI, Q., KAY, M.A., FINEGOLD, M., STARTFORD-PERRICAUDET, L.D., and WOO, S.L.C. (1993). Assessment of recombinant adenoviral vectors for hepatic gene therapy. Hum. Gene Ther. 4, 403-409.
13. POSTMUS, P.E., and SMIT, E.F. (1995). Oral therapy for small cell lung cancer. Lung Cancer 12, 63-70.
14. ROSENFELD, M.A., YOSHIMURA, K., TRAPNELL, B.C., YONEYAMA, K., ROSENTHAL, E.R., DALEMANS, W., FUKAYAMA, M., BARGON, J., STIER, L.E., STRATFORD-PERRICAUDET, L., PERRICAUDET, M., GUGGINO, W.B., PAVIRANI, A., LECOCQ, J.P., and CRYSTAL, R.G. (1992). In vivo transfer of the human cystic fibrosis transmembrane conductance regulator gene to the airway epithelium. Cell 68, 143-155.
15. STRATFORD-PERRICAUDET, L., LEVRERO, M., CHASSE, J., PERRICAUDET, M., and BRIAND, P. (1990). Evaluation of the transfer and expression in mice of an enzyme-encoding gene using a human adenovirus vector. Hum. Gene Ther. 1, 241-256.
16. VALLANCE, D.K., LYNCH, J.P., and McCUNE, W.J. (1995). Immunosuppressive treatment of the pulmonary manifestations of progressive systemic sclerosis. Curr. Opin. Rheumatol. 7, 174-182.
17. WEBER, G.F., and WAXMAN, D.J. (1993). Activation of the anti-cancer drug ifosphamide by rat liver microsomal P450 enzymes. Biochem. Pharmacol. 45, 1685-1694.
18. WILSON, J.M. (1995). Gene therapy for cystic fibrosis: Challenges and future directions. J. Clin. Invest. 96, 2547-2554.
19. YANG, Y., ERTL, H.C.J., and WILSON, J.M. (1994c). MHC class I-restricted cytotoxic T lymphocytes to viral antigens destroy hepatocytes in mice infected with E1-deleted recombinant adenoviruses. Immunity 1, 433-442.
20. YANG, Y., GREENOUGH, K., and WILSON, J.M. (1996). Transient immune blockade prevents formation of neutralizing antibody to recombinant adenovirus and allows repeated transfer to mouse liver. Gene Ther. 3, 412-420.
21. YANG, Y., LI, Q., ERTL, H.C., and WILSON, J. (1995a). Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenovirus. J. Virol. 69, 2004-2015.
22. YANG, Y., NUNES, F., BERENCSI, K., FURTH, E., GONCZOL, E., and WILSON, J. (1994b). Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc. Natl. Acad. Sci. USA 91, 4407-4411.
23. YANG, Y., NUNES, F.A., BERENCSI, K., GONCZOL, E., ENGELHARDT, J.E., and WILSON, J.M. (1994a). Inactivation of E2a in recombinant adenoviruses improves the prospect for gene therapy for cystic fibrosis. Nature Genet. 7, 362-369.
24. YANG, Y., TRINCHIERI, G., and WILSON, J.M. (1995c). Recombinant IL-12 prevents formation of blocking IgA antibodies to recombinant adenovirus and allows repeated gene therapy to mouse lung. Nature Med. 1, 890-893.
25. YANG, Y., XIANG, Z., ERTL, H.C.J., and WILSON, J.M. (1995b). Upregulation of class I MHC antigens by interferon-γ is necessary for the T cell-mediated elimination of recombinant adenovirus infected hepatocytes in vivo. Proc. Natl. Acad. Sci. USA 92, 7257-7261.
26. YEI, S., MITTEREDER, N., TANG, K., O'SULLIVAN, C., and TRAPNELL, B.C. (1994). Adenovirus-mediated gene transfer for cystic fibrosis: quantitative evaluation of repeated in vivo vector administration to the lung. Gene Ther. 1, 192-200.
27. ZSENGELLER, Z., WERT, S., HULL, W., HU, X., YEI, S., TRAPNELL, B., and WHITSETT, J. (1995). Persistence of replication-deficient adenovirus-mediated gene transfer in lungs of immune-deficient (nu/nu) mice. Hum. Gene Ther. 6, 457-467.